Ergoteles’s Corbus Pharmaceuticals CRBP Stock Holding History

Ergoteles’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-365	Closed	-$11K	–	1297
2021 Q3	$11K	Sell	365 -10,215	-97%	-$403K	﹤0.01%	1140
2021 Q2	$581K	Buy	+10,580	New	+$587K	0.01%	735

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Ergoteles's CRBP Position: Q4 2021 in Review

Ergoteles sold out of Corbus Pharmaceuticals (CRBP) in Q4 2021, closing a stake of 365 shares — an estimated $11K sold.

Ergoteles first reported a position in CRBP in Q2 2021 and held it in 2 quarters. The position peaked at $581K in Q2 2021. 82 funds tracked by Wall St. Rank hold CRBP as of Q4 2021.

Ergoteles reported no remaining Corbus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 365 Corbus Pharmaceuticals shares in Q4 2021, an estimated $11K.
Ergoteles first reported a position in Corbus Pharmaceuticals in Q2 2021 and held it in 2 quarters.
Ergoteles's Corbus Pharmaceuticals position peaked at $581K in Q2 2021.
82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.